Search

Displaying results 5401 - 5410 of 10000 in total
  1. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  2. Drug

    N-chlorotaurine

    go.drugbank.com/drugs/DB06633
    Experimental

    N-chlorotaurine is an inhibitor of inducible nitric oxide synthase and IkappaB kinase.

  3. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780]. … Diacerein is a prodrug which is metabolized to rhein.

  4. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    R1626 is very effective in inhibiting viral replication … R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors.

  5. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology.

  6. Drug

    Levobupivacaine

    go.drugbank.com/drugs/DB01002
    ApprovedInvestigationalWithdrawn

    Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. … It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal

    Synonyms: (S)-bupivacaine, (S)-1-butyl-2',6'-pipecoloxylidide
  7. Drug

    Aminocandin

    go.drugbank.com/drugs/DB05128
    Experimental

    Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.

  8. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … One minor metabolite, the isoprene, has the same potency as its parent compound.

  9. Drug

    Erdosteine

    go.drugbank.com/drugs/DB05057
    ApprovedInvestigational

    Erdosteine is a drug that causes a breakdown of mucus, also known as a _mucolytic_ agent. … Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.

  10. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH